



## Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference

August 29, 2018

SAN DIEGO , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it has been invited to present at the BioCentury 25<sup>th</sup> Annual NewsMakers in the Biotech Industry Conference on Friday, September 7, 2018, in New York.

Steven Mento, Ph.D., President and Chief Executive Officer of Conatus, is scheduled to present a corporate overview and business update at 10:30 a.m. ET. A webcast of the presentation will be available live and archived in the Investors section of the company's website at [www.conatuspharma.com](http://www.conatuspharma.com).

Host BioCentury handpicks only 48 companies to present their stories to biotech sector institutional investors. At the NewsMakers conference held in 2017, more than 500 delegates congregated at NewsMakers, including money managers who controlled more than \$600 billion in equity assets, with over \$50 billion dedicated to healthcare and \$15 billion dedicated to biotech.

### About Conatus Pharmaceuticals

Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. In collaboration with Novartis, Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, caspase inhibitors have the potential to interrupt the progression of a variety of diseases. For additional information, please visit [www.conatuspharma.com](http://www.conatuspharma.com).

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward looking statements, including statements regarding: caspase inhibitors' potential to interrupt the progression of a variety of diseases. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company's prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

**CONTACT:** Alan Engbring  
Conatus Pharmaceuticals Inc.  
(858) 376-2637  
[aengbring@conatuspharma.com](mailto:aengbring@conatuspharma.com)



Source: Conatus Pharmaceuticals Inc.